U.S. Pa Under the Paperwork Reduction Act of 1995, no persons are required to respond to a colle

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10774761			
Filing Date		2004-02-09			
First Named Inventor Kevir		J. Mills			
Art Unit	1:	2111			
Examiner Name AUVI		Glenn Allen			
Attorney Docket Number		SC 2002 9			

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date Name of Patentee of cited Document				Releva	es,Columns,Lines where vant Passages or Relevan res Appear		
	1	6976111	B1	2005-1	2-13	Mills et al.					
	2	6920517	B2	2005-0	7-19	Mills et al.					
	3	6863557	B2	2005-0	3-08	Mills et al.					
	4	5594873		1997-0	1-14	Garrett, James	s E.				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Releva	
	1										
If you wis	h to a	d additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Re	or Relevant	

#### 

	1												
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add												
NON-PATENT LITERATURE DOCUMENTS Remove													
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposisum, catalog, etc), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.						Ţ5						
	1												
If you wish to add additional non-patent literature document citation information please click the Add button Add													
EXAMINER SIGNATURE													
Examiner	Examiner Signature Date Considered							0					

See Kind Codes of USPTO Patent Documents at xwex\_USPTO\_CODV or MPEP 961.04. Enter office that assed the document, by the Noveleton (WIPO Standard ST3.). For Lapsanese patent document, the archaestor of the year of the region or the Emperor warp rescess the sent annumber of the opatent document. If Annual of Courrent by the appropriate symbols as enducated on the document under WIPO Standard ST.16 if possible. Speciant is to place a check mark here if Emploits around the courrent of the Courrent by the special terror and the courrent of the Courrent by the special terror and the courrent of the Courrent by the special terror and the courrent of the Courrent by the special terror and the courrent of the Courren

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10774761			
Filing Date		2004-02-09			
First Named Inventor	Kevin	J. Mills			
Art Unit		2111			
Examiner Name AUVE		, Glenn Allen			
Attorney Docket Number		SC.2002.9			

#### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a final representation of an accurate part foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. Sex 7 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	Signature	/Walstein Bennett Smith III/	Date (YYYY-MM-DD)	2006-04-09				
	Name/Print	Walstein Bennett Smith III	Registration Number	36685				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.